

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 April 2022 (28.04.2022)



(10) International Publication Number
WO 2022/087188 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/2803 (2006.01)
A61P 35/00 (2006.01) C07K 16/00 (2006.01)

(21) International Application Number:

PCT/US2021/055927

(22) International Filing Date:

20 October 2021 (20.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/094,354 21 October 2020 (21.10.2020) US
63/110,317 05 November 2020 (05.11.2020) US

(71) Applicant: IMMUNE-ONC THERAPEUTICS, INC.
[US/US]; 795 San Antonio Road, Palo Alto, California
94303 (US).

(72) Inventors: COSTA, Maria Jose; 795 San Antonio Road,
Palo Alto, California 94303 (US). STAFFORD, Ryan;
812 Peary Lane, Foster City, California 94404 (US). MC-
CUTCHEON, Krista; 1512 Carol Avenue, Burlingame,
California 94010 (US). MA, Jing-Tyan; 858 Lakeshore
Dr., Redwood City, California 94065 (US). HONG, Kyu
Hee; 4244 Juniper Lane, Palo Alto, California 94306 (US).
TIAN, Hongyu; 795 San Antonio Road, Palo Alto, Califor-
nia 94303 (US). SONG, An; 4260 Wilkie Way, Palo Alto,
California 94306 (US). LIAO, X. Charlene; 3751 Middle-
field Road, Palo Alto, California 94303 (US).

(74) Agent: ZHANG, Yi et al.; JUN HE LAW OFFICES P.C.,
20380 Town Center Lane, Suite 128, Cupertino, California
95014 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVATIVE PRODUCTS




Figure 3

(57) Abstract: The present disclosure provides anti-LILRB2 antibodies or antigen-binding fragments thereof, anti-LILRB2 chimeric antigen receptor protein, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*